rcca-header
Clinical Trials

A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

Type of Cancer
Breast Oncology
Phase
Division (Location)
Hackensack, NJ
Study ID
NCT#
Brief Description
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.